128 related articles for article (PubMed ID: 26113545)
1. A mouse model recapitulating human monoclonal heavy chain deposition disease evidences the relevance of proteasome inhibitor therapy.
Bonaud A; Bender S; Touchard G; Lacombe C; Srour N; Delpy L; Oblet C; Druilhe A; Quellard N; Javaugue V; Cogné M; Bridoux F; Sirac C
Blood; 2015 Aug; 126(6):757-65. PubMed ID: 26113545
[TBL] [Abstract][Full Text] [Related]
2. Unravelling the immunopathological mechanisms of heavy chain deposition disease with implications for clinical management.
Bridoux F; Javaugue V; Bender S; Leroy F; Aucouturier P; Debiais-Delpech C; Goujon JM; Quellard N; Bonaud A; Clavel M; Trouillas P; Di Meo F; Gombert JM; Fermand JP; Jaccard A; Cogné M; Touchard G; Sirac C
Kidney Int; 2017 Feb; 91(2):423-434. PubMed ID: 27773425
[TBL] [Abstract][Full Text] [Related]
3. Use of bortezomib in heavy-chain deposition disease: a report of 3 cases.
Patel K; Dillon JJ; Leung N; Bomback AS; Appel GB; D'Agati V; Canetta PA
Am J Kidney Dis; 2014 Jul; 64(1):123-7. PubMed ID: 24613055
[TBL] [Abstract][Full Text] [Related]
4. Immunoglobulin heavy chain gene rearrangement in heavy chain deposition disease suggests it is a plasma cell disease: a case report.
Rao Q; Xu R; Wan Q
J Int Med Res; 2022 Mar; 50(3):3000605221086428. PubMed ID: 35301906
[TBL] [Abstract][Full Text] [Related]
5. Renal crescentic alpha heavy chain deposition disease: a report of 3 cases and review of the literature.
Alexander MP; Nasr SH; Watson DC; Méndez GP; Rennke HG
Am J Kidney Dis; 2011 Oct; 58(4):621-5. PubMed ID: 21944962
[TBL] [Abstract][Full Text] [Related]
6. Sustained reduction of alloantibody secreting plasma cells and donor specific antibody with proteasome inhibition in mice.
Redfield RR; Lou Y; Rodriguez E; Rostami S; Parsons RF; Noorchashm H; Naji A; Abt PL
Transpl Immunol; 2013 Dec; 29(1-4):11-6. PubMed ID: 24103731
[TBL] [Abstract][Full Text] [Related]
7. [Renal disorders associated with monoclonal gammopathies: diagnostic and therapeutic progress].
Bridoux F; Delbes S; Sirac C; Pourreau F; Puyade M; Desport E; Jaccard A; Fermand JP; Touchard G
Presse Med; 2012 Mar; 41(3 Pt 1):276-89. PubMed ID: 22244725
[TBL] [Abstract][Full Text] [Related]
8. Immunoglobulin light-chain toxicity in a mouse model of monoclonal immunoglobulin light-chain deposition disease.
Bender S; Ayala MV; Bonaud A; Javaugue V; Carrion C; Oblet C; Rinsant A; Kaaki S; Oruc Z; Boyer F; Paquet A; Pons N; Hervé B; Ashi MO; Jaccard A; Delpy L; Touchard G; Cogné M; Bridoux F; Sirac C
Blood; 2020 Oct; 136(14):1645-1656. PubMed ID: 32559766
[TBL] [Abstract][Full Text] [Related]
9. Heavy chain deposition disease: recurrence in a renal transplant and report of IgG(2) subtype.
Herzenberg AM; Kiaii M; Magil AB
Am J Kidney Dis; 2000 May; 35(5):E25. PubMed ID: 10793054
[TBL] [Abstract][Full Text] [Related]
10. The proteasome inhibitor bortezomib prevents lupus nephritis in the NZB/W F1 mouse model by preservation of glomerular and tubulointerstitial architecture.
Hainz N; Thomas S; Neubert K; Meister S; Benz K; Rauh M; Daniel C; Wiesener M; Voll RE; Amann K
Nephron Exp Nephrol; 2012; 120(2):e47-58. PubMed ID: 22286140
[TBL] [Abstract][Full Text] [Related]
11. A case of renal γ2 heavy-chain deposition disease accompanied by rapid progressive renal failure.
Chen GT; Liao XH; Yan RY; Li Y; Zhang L
Ir J Med Sci; 2014 Jun; 183(2):319-21. PubMed ID: 23963539
[TBL] [Abstract][Full Text] [Related]
12. Heavy Chain Deposition Disease: Clinicopathologic Characteristics of a Chinese Case Series.
Zhang Y; Li X; Liang D; Xu F; Liang S; Zhu X; Zheng N; Huang X; Liu Z; Zeng C
Am J Kidney Dis; 2020 May; 75(5):736-743. PubMed ID: 31699519
[TBL] [Abstract][Full Text] [Related]
13. Clinical remission and histopathological resolution of nodular lesions in a patient with gamma3 heavy-chain deposition disease.
Soma J; Tsuchiya Y; Sakuma T; Sato H
Clin Nephrol; 2008 May; 69(5):383-6. PubMed ID: 18538103
[TBL] [Abstract][Full Text] [Related]
14. Proteasome inhibition aggravates tumor necrosis factor-mediated bone resorption in a mouse model of inflammatory arthritis.
Polzer K; Neubert K; Meister S; Frey B; Baum W; Distler JH; Gückel E; Schett G; Voll RE; Zwerina J
Arthritis Rheum; 2011 Mar; 63(3):670-80. PubMed ID: 21360496
[TBL] [Abstract][Full Text] [Related]
15. Proteasome inhibition for antibody-mediated allograft rejection.
Sadaka B; Alloway RR; Shields AR; Schmidt NM; Woodle ES
Semin Hematol; 2012 Jul; 49(3):263-9. PubMed ID: 22726550
[TBL] [Abstract][Full Text] [Related]
16. Randall-type monoclonal immunoglobulin deposition disease: novel insights from a nationwide cohort study.
Joly F; Cohen C; Javaugue V; Bender S; Belmouaz M; Arnulf B; Knebelmann B; Nouvier M; Audard V; Provot F; Gnemmi V; Nochy D; Goujon JM; Jaccard A; Touchard G; Fermand JP; Sirac C; Bridoux F
Blood; 2019 Feb; 133(6):576-587. PubMed ID: 30578255
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic enhancement of ER stress by insulin-like growth factor I sensitizes myeloma cells to proteasomal inhibitors.
Tagoug I; Jordheim LP; Herveau S; Matera EL; Huber AL; Chettab K; Manié S; Dumontet C
Clin Cancer Res; 2013 Jul; 19(13):3556-66. PubMed ID: 23674497
[TBL] [Abstract][Full Text] [Related]
18. Articular, monoclonal gamma3 heavy-chain deposition disease: characterization of a partially deleted heavy-chain gene and its protein product synthesized in vivo and in vitro.
Thompson KM; Sletten K; Brandtzaeg P; Källberg E; Wien TN; Husby G
Arthritis Rheum; 2003 Nov; 48(11):3266-71. PubMed ID: 14613292
[TBL] [Abstract][Full Text] [Related]
19. TNF potentiates anticancer activity of bortezomib (Velcade) through reduced expression of proteasome subunits and dysregulation of unfolded protein response.
Nowis D; McConnell EJ; Dierlam L; Palamarchuk A; Lass A; Wójcik C
Int J Cancer; 2007 Jul; 121(2):431-41. PubMed ID: 17373661
[TBL] [Abstract][Full Text] [Related]
20. Antitumor effects of proteasome inhibition in anaplastic thyroid carcinoma.
Altmann A; Markert A; Askoxylakis V; Schöning T; Jesenofsky R; Eisenhut M; Haberkorn U
J Nucl Med; 2012 Nov; 53(11):1764-71. PubMed ID: 23055533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
